The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and will take place prior to the 9th IAS Conference on HIV Science (IAS 2017) at the Campus des Cordeliers, Université Pierre et Marie-Curie (UPMC) in Paris, France.
Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting will also take advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It will also be an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.
The meeting will focus on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting will have a particular focus on access to care and new curative treatments especially for key populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics will be explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.